JP5801206B2 - アルツハイマー病の治療のための化合物および方法 - Google Patents

アルツハイマー病の治療のための化合物および方法 Download PDF

Info

Publication number
JP5801206B2
JP5801206B2 JP2011547867A JP2011547867A JP5801206B2 JP 5801206 B2 JP5801206 B2 JP 5801206B2 JP 2011547867 A JP2011547867 A JP 2011547867A JP 2011547867 A JP2011547867 A JP 2011547867A JP 5801206 B2 JP5801206 B2 JP 5801206B2
Authority
JP
Japan
Prior art keywords
seq
ctprosp
human
amino acid
isolated protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2011547867A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012521346A5 (https=
JP2012521346A (ja
Inventor
ヨハンソン、ヤン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AlphaBeta AB
Original Assignee
AlphaBeta AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AlphaBeta AB filed Critical AlphaBeta AB
Publication of JP2012521346A publication Critical patent/JP2012521346A/ja
Publication of JP2012521346A5 publication Critical patent/JP2012521346A5/ja
Application granted granted Critical
Publication of JP5801206B2 publication Critical patent/JP5801206B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/395—Alveolar surfactant peptides; Pulmonary surfactant peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/785—Alveolar surfactant peptides; Pulmonary surfactant peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2011547867A 2009-01-30 2010-01-29 アルツハイマー病の治療のための化合物および方法 Active JP5801206B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US14854109P 2009-01-30 2009-01-30
EP09151790 2009-01-30
US61/148,541 2009-01-30
EP09151790.4 2009-01-30
PCT/SE2010/050097 WO2010087771A1 (en) 2009-01-30 2010-01-29 Compound and method for treatment of alzheimer's disease

Publications (3)

Publication Number Publication Date
JP2012521346A JP2012521346A (ja) 2012-09-13
JP2012521346A5 JP2012521346A5 (https=) 2014-03-27
JP5801206B2 true JP5801206B2 (ja) 2015-10-28

Family

ID=40707673

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011547867A Active JP5801206B2 (ja) 2009-01-30 2010-01-29 アルツハイマー病の治療のための化合物および方法

Country Status (5)

Country Link
US (2) US8785390B2 (https=)
EP (1) EP2391379B1 (https=)
JP (1) JP5801206B2 (https=)
CN (1) CN102300582A (https=)
WO (1) WO2010087771A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102300582A (zh) * 2009-01-30 2011-12-28 阿尔法贝塔公司 用于治疗阿尔茨海默病的化合物和方法
WO2011162655A1 (en) 2010-06-24 2011-12-29 Alphabeta Ab Compound and method for treatment of alzheimer's disease and familial dementia
WO2012138284A1 (en) * 2011-04-05 2012-10-11 Alphabeta Ab Amyloidosis target useful in methods of treatment and for screening of compounds
ES2571055B1 (es) * 2016-02-15 2016-12-28 Araclon Biotech, S.L. Conjugado amiloide y usos y procedimientos del mismo
CN114107254A (zh) * 2021-11-12 2022-03-01 武汉理工大学 一种重组蛋白DspB-SNa5及其制备方法和应用

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0290516A4 (en) 1986-10-24 1989-11-14 Jeffrey A Whitsett PROTEINS RELATED TO SURFACE-EFFECTIVE HYDROPHOBIC LUNG ACTIVE SUBSTANCES.
US6670195B1 (en) 1999-05-26 2003-12-30 New York University Mutant genes in Familial British Dementia and Familial Danish Dementia
US20030224982A1 (en) * 2001-07-05 2003-12-04 Li Li Therapeutic polypeptides, nucleic acids encoding same, and methods of use
US6673545B2 (en) 2000-07-28 2004-01-06 Incyte Corporation Prostate cancer markers
US6716589B2 (en) 2000-11-20 2004-04-06 Alphabeta Ab Discordant helix stabilization for prevention of amyloid formation
WO2003090682A2 (en) * 2002-04-25 2003-11-06 The Scripps Research Institute Treatment and prevention of pulmonary conditions
WO2004056310A2 (en) 2002-12-09 2004-07-08 Children's Hospital Medical Center Methods of diagnosis and treatment of interstitial lung disease
GB0307863D0 (en) * 2003-04-04 2003-05-14 Merck Sharp & Dohme Therapeutic treatment
CA2537844A1 (en) 2003-09-05 2005-03-17 Cellzome Ag Treatment of neurodegenerative diseases
JP4796967B2 (ja) 2003-11-07 2011-10-19 ヴァーミリオン インコーポレイテッド アルツハイマー病のためのバイオマーカー
AU2004296206A1 (en) * 2003-12-04 2005-06-23 The Scripps Research Institute Treatment and preventions of asthma
CA2579710C (en) 2004-04-05 2013-01-08 The University Of Tokushima Antigen-drug vehicle enabling transmucosal and transdermal administration, and method of inducing mucosal immunity and mucosal vaccine and dds using the same
AU2006259482A1 (en) 2005-06-14 2006-12-28 Albert Einstein College Of Medicine Of Yeshiva University Effect of BRI proteins on abeta production
WO2007005672A2 (en) * 2005-06-30 2007-01-11 The Scripps Research Institute Treatment and prevention of respiratory diseases and conditions
EP1930025B1 (en) 2005-08-05 2013-05-01 The University of Tokushima ANTIGEN-AND-DRUG VEHICLE WHICH ENABLES THE CHANGEOVER FROM THE SELECTIVE PRODUCTION OF IgA ANTIBODY TO THE PRODUCTION OF BOTH OF IgA AND IgG ANTIBODIES, AND TRANSNASAL/TRANSMUCOSAL VACCINE USING THE VEHICLE
CA2706535A1 (en) 2006-11-22 2008-06-05 Albert Einstein College Of Medicine Of Yeshiva University Transgenic mammals modified in bri protein expression
US20100284969A1 (en) 2007-06-05 2010-11-11 Frank Guarnieri Methods and Compositions for Delivery of Medicaments to the Lungs
US20100298202A1 (en) * 2007-07-06 2010-11-25 Mayo Foundation For Medical Education And Research Bri polypeptides and reducing ab aggregation
CN102300582A (zh) 2009-01-30 2011-12-28 阿尔法贝塔公司 用于治疗阿尔茨海默病的化合物和方法
WO2011162655A1 (en) 2010-06-24 2011-12-29 Alphabeta Ab Compound and method for treatment of alzheimer's disease and familial dementia
WO2012138284A1 (en) 2011-04-05 2012-10-11 Alphabeta Ab Amyloidosis target useful in methods of treatment and for screening of compounds

Also Published As

Publication number Publication date
EP2391379A1 (en) 2011-12-07
JP2012521346A (ja) 2012-09-13
EP2391379A4 (en) 2012-11-28
CN102300582A (zh) 2011-12-28
US9402883B2 (en) 2016-08-02
EP2391379B1 (en) 2017-08-02
WO2010087771A8 (en) 2011-08-25
WO2010087771A1 (en) 2010-08-05
US20140243272A1 (en) 2014-08-28
US20120122794A1 (en) 2012-05-17
US8785390B2 (en) 2014-07-22

Similar Documents

Publication Publication Date Title
JP5893614B2 (ja) アルツハイマー病および家族性認知症の治療のための化合物および方法
EP2891661A1 (en) Mitochondrial targeting peptide
JP5801206B2 (ja) アルツハイマー病の治療のための化合物および方法
US20180319860A1 (en) Islet amyloid polypeptides with improved solubility
JP2025163012A (ja) レトロインベルソペプチド
Magami et al. A single Asp isomer substitution in an αA-crystallin-derived peptide induces a large change in peptide properties
EP2694977B1 (en) Amyloidosis target useful in methods of screening of compounds
JP5179198B2 (ja) アミロイドベータ−ペプチドの凝集を低減する化合物
US10400009B2 (en) β-sheet breaker peptide used for preventing and/or treating alzheimer's disease
US20230391841A1 (en) Macrocyclic peptides
JP6258282B2 (ja) アルツハイマー病および家族性認知症の治療のための化合物および方法
US20230203107A1 (en) Peptide for treating sepsis derived from rv3364c protein of mycobacterium tuberculosis
WO2023081825A2 (en) Active immunization against amyloid and aging-related diseases
JP2008019245A (ja) ヒューマニン誘導体又は該誘導体と神経向性ペプチドとの融合ペプチドを有効成分として含有する、アルツハイマー病予防・治療用の経鼻投与剤

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130128

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20130128

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140204

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140610

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140909

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20150210

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150609

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20150617

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20150728

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20150826

R150 Certificate of patent or registration of utility model

Ref document number: 5801206

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250